Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/nm1209-1358 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Silencing of the plant-derived horizontally transferred gene BtSC5DL effectively controls Bemisia tabaci MED.
Pest Manag Sci
January 2025
College of Plant Protection, Hunan Agricultural University, Changsha, China.
Background: The whitefly Bemisia tabaci is a notorious agricultural pest known for its ability to cause significant crop damage through direct feeding and virus transmission. Its remarkable adaptability and reproductive capacity are linked to its ability to acquire and integrate horizontally transferred genes (HTGs) into its genome. These HTGs increase the physiological and metabolic capacities of this pest, including cholesterol synthesis, which is critical for its survival and reproductive success.
View Article and Find Full Text PDFHeat-Induced Phosphatidylserine Changes Drive HSPA1A's Plasma Membrane Localization.
bioRxiv
December 2024
Department of Biological Science, Center for Applied Biotechnology Studies, and Center for Computational and Applied Mathematics, California State University Fullerton, Fullerton, CA, USA.
Heat shock protein A1A (HSPA1A) is a molecular chaperone crucial in cell survival. In addition to its cytosolic functions, HSPA1A translocates to heat-shocked and cancer cells' plasma membrane (PM). In cancer, PM-localized HSPA1A (mHSPA1A) is associated with increased tumor aggressiveness and therapeutic resistance, suggesting that preventing its membrane localization could have therapeutic value.
View Article and Find Full Text PDFNew drugs for treating dyslipidemias. From small molecules to small interfering RNAs.
Clin Investig Arterioscler
December 2024
Unitat de Recerca en Lípids i Arteriosclerosi, Unitat de Medicina Vascular i Metabolisme, Hospital Universitari Sant Joan, Universitat Rovira i Virgili, IISPV, CIBERDEM, Reus, Tarragona, España.
Article Synopsis
- - Despite available therapies, many patients still fail to meet their cardiovascular health goals, and cardiovascular diseases are a major cause of death.
- - Even patients who lower their LDL-C levels to recommended targets experience ongoing cardiovascular events, highlighting the need for new treatment options.
- - Research is focusing on innovative drugs and mechanisms, including small molecules and RNA interference, with inclisiran being the first approved drug for cardiovascular use; this review discusses emerging therapeutic targets and their potential effects.
Lipoprotein (a): Underrecognized Risk with a Promising Future.
Rev Cardiovasc Med
November 2024
Department of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Lipoprotein a (Lp(a)) is a lipid biomarker that binds cholesterol and bears independent cardiovascular risk. Strategies to lower the level of Lp(a) and mitigate such risk are important both for primary and secondary prevention. Currently there are no approved therapies targeting Lp(a) directly.
View Article and Find Full Text PDFMessenger interference RNA therapies targeting apolipoprotein C-III and angiopoietin-like protein 3 for mixed hyperlipidemia: the future of plozasiran and zodasiran.
Expert Rev Clin Pharmacol
November 2024
Department of Internal Medicine, MedStar Washington Hospital Center, Washington, DC, USA.
Introduction: Mixed hyperlipidemia represents a substantial public health issue and a considerable burden on healthcare systems. Although the introduction of statins and LDL-cholesterol lowering agents have significantly reduced the incidence of atherosclerotic cardiovascular diseases (ASCVD), a significant portion of the population continues to exhibit ASCVD progression due to elevated triglyceride-rich lipoprotein (TRL) levels. This persistent risk has catalyzed the development of novel pharmacological interventions targeting these lipoproteins.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!